Literature DB >> 20373018

Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.

Monica Zuradelli1, Bernard Peissel, Siranoush Manoukian, Daniela Zaffaroni, Monica Barile, Valeria Pensotti, Ugo Cavallari, Giovanna Masci, Frederique Mariette, Anne Caroline Benski, Armando Santoro, Paolo Radice.   

Abstract

Double heterozygosity (DH) for BRCA1 and BRCA2 mutations is a very rare finding, particularly in non-Ashkenazi individuals, and only a few cases have been reported to date. In addition, little is known on the pathological features of the tumors that occur in DH cases and on their family history of cancer. Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions. Clinical, pathological, and family history data were collected from medical records and during genetic counseling sessions. All identified DH cases developed breast carcinoma and three of them were also diagnosed with ovarian carcinoma. Mean ages of breast and ovarian cancer diagnosis were 42.7 and 48.6 years, respectively. The majority of breast cancers showed a BRCA1-related phenotype, being negative for hormone receptors and HER2. Two cases reported different gastrointestinal tumors among relatives. Although the individuals described in this study show more severe clinical features in comparison to previously reported BRCA1 and BRCA2 DH cases, our observations support the hypothesis of a non specific phenotype of DH cases in terms of age of disease onset. In addition, our observations indicate that in DH patients breast carcinogenesis appears to be driven mainly by the mutations in BRCA1. The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373018     DOI: 10.1007/s10549-010-0853-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.

Authors:  Jarbas Maciel de Oliveira; Nuria Bengala Zurro; Antonio Victor Campos Coelho; Marcel Pinheiro Caraciolo; Rodrigo Bertollo de Alexandre; Murilo Castro Cervato; Renata Moldenhauer Minillo; George de Vasconcelos Carvalho Neto; Ivana Grivicich; João Bosco Oliveira
Journal:  Eur J Hum Genet       Date:  2022-05-09       Impact factor: 5.351

2.  How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?

Authors:  Ava Kwong; Cecilia Yuen Sze Ho; Vivian Yvonne Shin; Chun Hang Au; Tsun-Leung Chan; Edmond Shiu Kwan Ma
Journal:  BMC Med Genomics       Date:  2022-05-31       Impact factor: 3.622

3.  Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

Authors:  Timothy R Rebbeck; Tara M Friebel; Nandita Mitra; Fei Wan; Stephanie Chen; Irene L Andrulis; Paraskevi Apostolou; Norbert Arnold; Banu K Arun; Daniel Barrowdale; Javier Benitez; Raanan Berger; Pascaline Berthet; Ake Borg; Saundra S Buys; Trinidad Caldes; Jonathan Carter; Jocelyne Chiquette; Kathleen B M Claes; Fergus J Couch; Cezary Cybulski; Mary B Daly; Miguel de la Hoya; Orland Diez; Susan M Domchek; Katherine L Nathanson; Katarzyna Durda; Steve Ellis; D Gareth Evans; Lenka Foretova; Eitan Friedman; Debra Frost; Patricia A Ganz; Judy Garber; Gord Glendon; Andrew K Godwin; Mark H Greene; Jacek Gronwald; Eric Hahnen; Emily Hallberg; Ute Hamann; Thomas V O Hansen; Evgeny N Imyanitov; Claudine Isaacs; Anna Jakubowska; Ramunas Janavicius; Katarzyna Jaworska-Bieniek; Esther M John; Beth Y Karlan; Bella Kaufman; KConFab Investigators; Ava Kwong; Yael Laitman; Christine Lasset; Conxi Lazaro; Jenny Lester; Niklas Loman; Jan Lubinski; Siranoush Manoukian; Gillian Mitchell; Marco Montagna; Susan L Neuhausen; Heli Nevanlinna; Dieter Niederacher; Robert L Nussbaum; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Sue Kyung Park; Marion Piedmonte; Paolo Radice; Christine Rappaport-Fuerhauser; Matti A Rookus; Caroline Seynaeve; Jacques Simard; Christian F Singer; Penny Soucy; Melissa Southey; Dominique Stoppa-Lyonnet; Grzegorz Sukiennicki; Csilla I Szabo; Mariella Tancredi; Manuel R Teixeira; Soo-Hwang Teo; Mary Beth Terry; Mads Thomassen; Laima Tihomirova; Marc Tischkowitz; Amanda Ewart Toland; Aleksandra Toloczko-Grabarek; Nadine Tung; Elizabeth J van Rensburg; Danylo Villano; Shan Wang-Gohrke; Barbara Wappenschmidt; Jeffrey N Weitzel; Jamal Zidan; Kristin K Zorn; Lesley McGuffog; Douglas Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Susan J Ramus
Journal:  Breast Cancer Res       Date:  2016-11-11       Impact factor: 6.466

4.  Five Italian Families with Two Mutations in BRCA Genes.

Authors:  Maria Teresa Vietri; Gemma Caliendo; Giovanna D'Elia; Marianna Resse; Amelia Casamassimi; Pellegrino Biagio Minucci; Concetta Dello Ioio; Michele Cioffi; Anna Maria Molinari
Journal:  Genes (Basel)       Date:  2020-12-03       Impact factor: 4.096

5.  A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2.

Authors:  Miyuki Kitahara; Yasuo Hozumi; Mitsuki Machinaga; Yuka Hayashi
Journal:  Case Rep Oncol       Date:  2021-11-18

6.  Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family.

Authors:  Raffaele Palmirotta; Domenica Lovero; Luigia Stefania Stucci; Erica Silvestris; Davide Quaresmini; Angela Cardascia; Franco Silvestris
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.